Prospective and Retrospective Multicenter Cohort Study of Patients With Chronic Hepatitis C Treated by Peginterferon Alfa-2b Plus Ribaviri
Phase 4
- Conditions
- Chronic Hepatitis C
- Registration Number
- JPRN-UMIN000003976
- Lead Sponsor
- Department of Gastroenterology The University of Tokyo Hospital
- Brief Summary
The rate of SVR was 55%.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
Any contraindication to peginterferon alfa-2b + ribavirin therapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sustained virological response 24 weeks after the end of treatment
- Secondary Outcome Measures
Name Time Method Safety